{
  "slug": "natera-signatera",
  "name": "Natera (Signatera)",
  "description": "Natera is a global leader in cell-free DNA (cfDNA) testing, specializing in oncology, women's health, and organ health. Its flagship oncology product, Signatera, is a personalized, tumor-informed molecular residual disease (MRD) test designed to detect cancer recurrence earlier than standard imaging.",
  "url": "https://optimly.ai/brand/natera-signatera",
  "logoUrl": "",
  "baiScore": 88,
  "archetype": "Challenger",
  "category": "Biotechnology",
  "categorySlug": null,
  "keyFacts": [],
  "aiReadiness": [],
  "competitors": [],
  "inboundCompetitors": [
    {
      "slug": "personalis-next-personal",
      "name": "Personalis (NeXT Personal)"
    }
  ],
  "aiAlternatives": [],
  "parentBrand": null,
  "subBrands": [],
  "updatedAt": "2026-04-10T04:05:31.174+00:00",
  "verifiedVitals": {
    "website": "natera.com",
    "founded": "2004",
    "headquarters": "Austin, Texas",
    "pricing_model": "Insurance-based/Enterprise Custom (Medical Billing)",
    "core_products": "Signatera (Oncology MRD), Panorama (NIPT), Horizon (Carrier Screening), Prospera (Organ Health)",
    "key_differentiator": "Signatera is a tumor-informed assay, meaning it is custom-built for each patient based on their unique tumor signature, offering higher sensitivity than generic 'tumor-naive' liquid biopsies.",
    "target_markets": "Oncology, Reproductive Health, Nephrology, Transplant Medicine",
    "employee_count": "3,000+",
    "funding_stage": "Public (NASDAQ: NTRA)",
    "subcategory": "Molecular Diagnostics"
  },
  "intentTags": {
    "problemIntents": [
      "Standard Radiographic Imaging: Surgical oncologists and radiologists monitoring for recurrence using standard medical imaging (CT, MRI) without molecular enhancement.",
      "Traditional Protein Biomarkers: Monitoring patients through serial measurements of traditional protein-based tumor markers like CEA or CA-125."
    ],
    "solutionIntents": [
      "Best MRD test for colorectal cancer recurrence",
      "personalized liquid biopsy for cancer monitoring",
      "cfDNA testing for oncology",
      "Signatera Medicare coverage indications",
      "how to get a blood test for cancer at home",
      "Tissue-only Pathology: Using standard tissue biopsies at the time of suspected recurrence rather than proactive blood-based monitoring."
    ],
    "evaluationIntents": []
  },
  "timestamp": 1777659455524
}